. Author manuscript; available in PMC: 2022 Nov 3.

Published in final edited form as: BMJ Support Palliat Care. 2023 Dec 7;13(e2):e344–e351. doi: 10.1136/bmjspcare-2020-002312

Table 2.

Distribution of fatigue scores and adjusted mean differences between patients with AML and the general population (n=463).

	Distribution of fatigue scores			Adjusted mean difference from general population^* (95% CI)	p
Sample	Mean (SD)	Median	Range	Adjusted mean difference from general population^* (95% CI)	p
General population	40.5 (10.2)	44.0	2–52	NA	NA
AML total sample	33.1 (8.7)	33.8	0–52	−7.5 (−8.6, −6.4)	<0.001
NCCN risk category
Favorable	33.9 (7.8)	34.7	13–52	−6.7 (−8.6, −4.8)	<0.001
Intermediate	34.0 (8.3)	34.3	8–51	−6.8 (−8.5, −5.1)	<0.001
Poor	31.8 (9.4)	31.9	0–50	−8.9 (−10.5, −7.2)	<0.001

Mean differences were adjusted for age and sex;

Abbreviations: SD, standard deviation; CI, confidence interval; NA, not applicable. AML, acute myeloid leukemia; NCCN, National Comprehensive Cancer Network.